Therefore, these coincident results support the initial idea of the study, encouraging us to perform subsequent immunological analyses to detect their presence in sera, plasma or CSF to determine the usefulness of the altered signaling molecules LGALS3BP, Layilin, MICB, and DDIT3 as blood- or CSF-based AD diagnostic biomarkers. The gene discussed is LGALS3BP; the disease is Alzheimer disease.